Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest

C. William Hanke, Brian Berman, Neil Swanson, David M. Pariser, Jonathan S. Weiss, Michael Bukhalo, Torsten Skov, John Villumsen, Daniel Siegel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Actinic keratosis (AK) can affect large skin areas. Ingenol mebutate (IngMeb) gel (0.015% and 0.05%) is approved for topical treatment of AK in a single contiguous area of ~25 cm2. Objective: The study sought to determine the maximum tolerated dose (MTD), efficacy, and tolerability of IngMeb applied to AK on a contiguous area less than equal to 250 cm2. Methods: Part 1 determined the MTD of IngMeb at 7 concentrations for 2 or 3 days. Part 2 assessed efficacy and tolerability at the MTD and one dose lower for 2 or 3 days vs vehicle. Results: Four dosing regimens with an acceptable benefit-to-risk ratio were identified: 0.018% and 0.027% once daily for 2 or 3 days. Complete clearance at 8 weeks was achieved by 21.3% to 39.1% of IngMeb-treated patients vs 0% to 3.2% treated with vehicle. Composite local skin response scores peaked on the day after the last application, rapidly declined, and were near baseline at 2 weeks. Adverse events were predominantly mild or moderate. Limitations: The study evaluated a limited number of doses in a population of only white patients. Conclusion: IngMeb gel was effective and well tolerated as field treatment of AK on the full face, full scalp, and up to 250 cm2 on the chest. D

Original languageEnglish (US)
Pages (from-to)438-444
Number of pages7
JournalJournal of Drugs in Dermatology
Volume16
Issue number5
StatePublished - May 1 2017

Fingerprint

Actinic Keratosis
Scalp
Thorax
Maximum Tolerated Dose
Safety
Gels
Therapeutics
Skin
Odds Ratio
3-ingenyl angelate
Population

ASJC Scopus subject areas

  • Dermatology

Cite this

Hanke, C. W., Berman, B., Swanson, N., Pariser, D. M., Weiss, J. S., Bukhalo, M., ... Siegel, D. (2017). Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest. Journal of Drugs in Dermatology, 16(5), 438-444.

Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest. / Hanke, C. William; Berman, Brian; Swanson, Neil; Pariser, David M.; Weiss, Jonathan S.; Bukhalo, Michael; Skov, Torsten; Villumsen, John; Siegel, Daniel.

In: Journal of Drugs in Dermatology, Vol. 16, No. 5, 01.05.2017, p. 438-444.

Research output: Contribution to journalArticle

Hanke, CW, Berman, B, Swanson, N, Pariser, DM, Weiss, JS, Bukhalo, M, Skov, T, Villumsen, J & Siegel, D 2017, 'Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest', Journal of Drugs in Dermatology, vol. 16, no. 5, pp. 438-444.
Hanke, C. William ; Berman, Brian ; Swanson, Neil ; Pariser, David M. ; Weiss, Jonathan S. ; Bukhalo, Michael ; Skov, Torsten ; Villumsen, John ; Siegel, Daniel. / Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest. In: Journal of Drugs in Dermatology. 2017 ; Vol. 16, No. 5. pp. 438-444.
@article{5b99f5b865d846408f9c84bcbf7f23a0,
title = "Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest",
abstract = "Background: Actinic keratosis (AK) can affect large skin areas. Ingenol mebutate (IngMeb) gel (0.015{\%} and 0.05{\%}) is approved for topical treatment of AK in a single contiguous area of ~25 cm2. Objective: The study sought to determine the maximum tolerated dose (MTD), efficacy, and tolerability of IngMeb applied to AK on a contiguous area less than equal to 250 cm2. Methods: Part 1 determined the MTD of IngMeb at 7 concentrations for 2 or 3 days. Part 2 assessed efficacy and tolerability at the MTD and one dose lower for 2 or 3 days vs vehicle. Results: Four dosing regimens with an acceptable benefit-to-risk ratio were identified: 0.018{\%} and 0.027{\%} once daily for 2 or 3 days. Complete clearance at 8 weeks was achieved by 21.3{\%} to 39.1{\%} of IngMeb-treated patients vs 0{\%} to 3.2{\%} treated with vehicle. Composite local skin response scores peaked on the day after the last application, rapidly declined, and were near baseline at 2 weeks. Adverse events were predominantly mild or moderate. Limitations: The study evaluated a limited number of doses in a population of only white patients. Conclusion: IngMeb gel was effective and well tolerated as field treatment of AK on the full face, full scalp, and up to 250 cm2 on the chest. D",
author = "Hanke, {C. William} and Brian Berman and Neil Swanson and Pariser, {David M.} and Weiss, {Jonathan S.} and Michael Bukhalo and Torsten Skov and John Villumsen and Daniel Siegel",
year = "2017",
month = "5",
day = "1",
language = "English (US)",
volume = "16",
pages = "438--444",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "5",

}

TY - JOUR

T1 - Safety and efficacy of escalating doses of ingenol mebutate for field treatment of actinic keratosis on the full face, full balding scalp, or chest

AU - Hanke, C. William

AU - Berman, Brian

AU - Swanson, Neil

AU - Pariser, David M.

AU - Weiss, Jonathan S.

AU - Bukhalo, Michael

AU - Skov, Torsten

AU - Villumsen, John

AU - Siegel, Daniel

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Actinic keratosis (AK) can affect large skin areas. Ingenol mebutate (IngMeb) gel (0.015% and 0.05%) is approved for topical treatment of AK in a single contiguous area of ~25 cm2. Objective: The study sought to determine the maximum tolerated dose (MTD), efficacy, and tolerability of IngMeb applied to AK on a contiguous area less than equal to 250 cm2. Methods: Part 1 determined the MTD of IngMeb at 7 concentrations for 2 or 3 days. Part 2 assessed efficacy and tolerability at the MTD and one dose lower for 2 or 3 days vs vehicle. Results: Four dosing regimens with an acceptable benefit-to-risk ratio were identified: 0.018% and 0.027% once daily for 2 or 3 days. Complete clearance at 8 weeks was achieved by 21.3% to 39.1% of IngMeb-treated patients vs 0% to 3.2% treated with vehicle. Composite local skin response scores peaked on the day after the last application, rapidly declined, and were near baseline at 2 weeks. Adverse events were predominantly mild or moderate. Limitations: The study evaluated a limited number of doses in a population of only white patients. Conclusion: IngMeb gel was effective and well tolerated as field treatment of AK on the full face, full scalp, and up to 250 cm2 on the chest. D

AB - Background: Actinic keratosis (AK) can affect large skin areas. Ingenol mebutate (IngMeb) gel (0.015% and 0.05%) is approved for topical treatment of AK in a single contiguous area of ~25 cm2. Objective: The study sought to determine the maximum tolerated dose (MTD), efficacy, and tolerability of IngMeb applied to AK on a contiguous area less than equal to 250 cm2. Methods: Part 1 determined the MTD of IngMeb at 7 concentrations for 2 or 3 days. Part 2 assessed efficacy and tolerability at the MTD and one dose lower for 2 or 3 days vs vehicle. Results: Four dosing regimens with an acceptable benefit-to-risk ratio were identified: 0.018% and 0.027% once daily for 2 or 3 days. Complete clearance at 8 weeks was achieved by 21.3% to 39.1% of IngMeb-treated patients vs 0% to 3.2% treated with vehicle. Composite local skin response scores peaked on the day after the last application, rapidly declined, and were near baseline at 2 weeks. Adverse events were predominantly mild or moderate. Limitations: The study evaluated a limited number of doses in a population of only white patients. Conclusion: IngMeb gel was effective and well tolerated as field treatment of AK on the full face, full scalp, and up to 250 cm2 on the chest. D

UR - http://www.scopus.com/inward/record.url?scp=85028991025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028991025&partnerID=8YFLogxK

M3 - Article

C2 - 28628679

AN - SCOPUS:85028991025

VL - 16

SP - 438

EP - 444

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 5

ER -